We hypothesize that the heterogeneity in tumor latency and the timing of treatment delivery may have conferred a significant survival benefit that was difficult to detect compared with the genetic loss of Atm and compared with the pharmacological xenograft experiment. This evidence concerns the gene ATM and neoplasm.